{"title":"靶向胸腺基质淋巴生成素治疗鼻2型炎症","authors":"Xintong Li, Jingjing Guo, Jing Song, Ming Wang","doi":"10.1002/eer3.70023","DOIUrl":null,"url":null,"abstract":"<p>Epithelial cell-derived thymic stromal lymphopoietin (TSLP) plays a crucial role in mediating type 2 immune responses, which is one of the key underlying pathophysiological mechanisms of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with nasal polyps (CRSwNP). Researches show that inhibiting TSLP signaling has significant therapeutic potential in alleviating type 2 inflammation. Biologics targeting TSLP have been developed and introduced into clinical practice, yielding promising therapeutic outcomes, especially in asthma. Several anti-TSLP antibodies are undergoing clinical trials to investigate the efficacy and safety in treating CRSwNP and AR. This review aims to delve into the latest progress regarding the functional role of TSLP, the clinical outcomes associated with anti-TSLP therapies, and the therapeutic potential of anti-TSLP antibodies in treating nasal type 2 inflammation.</p>","PeriodicalId":100519,"journal":{"name":"Eye & ENT Research","volume":"2 3","pages":"164-172"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70023","citationCount":"0","resultStr":"{\"title\":\"Targeting thymic stromal lymphopoietin in nasal type 2 inflammation\",\"authors\":\"Xintong Li, Jingjing Guo, Jing Song, Ming Wang\",\"doi\":\"10.1002/eer3.70023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Epithelial cell-derived thymic stromal lymphopoietin (TSLP) plays a crucial role in mediating type 2 immune responses, which is one of the key underlying pathophysiological mechanisms of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with nasal polyps (CRSwNP). Researches show that inhibiting TSLP signaling has significant therapeutic potential in alleviating type 2 inflammation. Biologics targeting TSLP have been developed and introduced into clinical practice, yielding promising therapeutic outcomes, especially in asthma. Several anti-TSLP antibodies are undergoing clinical trials to investigate the efficacy and safety in treating CRSwNP and AR. This review aims to delve into the latest progress regarding the functional role of TSLP, the clinical outcomes associated with anti-TSLP therapies, and the therapeutic potential of anti-TSLP antibodies in treating nasal type 2 inflammation.</p>\",\"PeriodicalId\":100519,\"journal\":{\"name\":\"Eye & ENT Research\",\"volume\":\"2 3\",\"pages\":\"164-172\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eer3.70023\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eye & ENT Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/eer3.70023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye & ENT Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/eer3.70023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Targeting thymic stromal lymphopoietin in nasal type 2 inflammation
Epithelial cell-derived thymic stromal lymphopoietin (TSLP) plays a crucial role in mediating type 2 immune responses, which is one of the key underlying pathophysiological mechanisms of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with nasal polyps (CRSwNP). Researches show that inhibiting TSLP signaling has significant therapeutic potential in alleviating type 2 inflammation. Biologics targeting TSLP have been developed and introduced into clinical practice, yielding promising therapeutic outcomes, especially in asthma. Several anti-TSLP antibodies are undergoing clinical trials to investigate the efficacy and safety in treating CRSwNP and AR. This review aims to delve into the latest progress regarding the functional role of TSLP, the clinical outcomes associated with anti-TSLP therapies, and the therapeutic potential of anti-TSLP antibodies in treating nasal type 2 inflammation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
